Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Frye

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|January 1, 1997
Effects of liver disease on the disposition of the opioid antagonist nalmefeneR F Frye, G R Matzke, R Schade, et al.
The International Journal of Artificial Organs|October 8, 2005
Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patientsR J Elwell, H J Manley, R F Frye, et al.
Pharmacotherapy|June 15, 2000
Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysisG R Matzke, R F Frye, M S Joy, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|October 6, 2001
Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patientsH J Manley, G R Bailie, R F Frye, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Effect of ceftazidime on systemic cytokine concentrations in ratsK M Alkharfy, J A Kellum, R F Frye, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 18, 1998
Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrationsM A Marx, R F Frye, G R Matzke, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysisG R Matzke, R F Frye, M S Joy, et al.
Kidney International|January 3, 2001
Characterization of tubular functional capacity in humans using para-aminohippurate and famotidineT C Dowling, R F Frye, D S Fraley, et al.
Alimentary Pharmacology & Therapeutics|May 5, 2017
Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitisM Kawaguchi-Suzuki, F Bril, S Kalavalapalli, et al.
Clinical Pharmacology and Therapeutics|November 4, 2000
In vivo modulation of CYP enzymes by quinidine and rifampinR A Branch, A Adedoyin, R F Frye, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|January 1, 1997
Effects of liver disease on the disposition of the opioid antagonist nalmefeneR F Frye, G R Matzke, R Schade, et al.
The International Journal of Artificial Organs|October 8, 2005
Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patientsR J Elwell, H J Manley, R F Frye, et al.
Pharmacotherapy|June 15, 2000
Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysisG R Matzke, R F Frye, M S Joy, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|October 6, 2001
Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patientsH J Manley, G R Bailie, R F Frye, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Effect of ceftazidime on systemic cytokine concentrations in ratsK M Alkharfy, J A Kellum, R F Frye, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 18, 1998
Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrationsM A Marx, R F Frye, G R Matzke, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysisG R Matzke, R F Frye, M S Joy, et al.
Kidney International|January 3, 2001
Characterization of tubular functional capacity in humans using para-aminohippurate and famotidineT C Dowling, R F Frye, D S Fraley, et al.
Alimentary Pharmacology & Therapeutics|May 5, 2017
Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitisM Kawaguchi-Suzuki, F Bril, S Kalavalapalli, et al.
Clinical Pharmacology and Therapeutics|November 4, 2000
In vivo modulation of CYP enzymes by quinidine and rifampinR A Branch, A Adedoyin, R F Frye, et al.
Pageof 5